LCTX - Lineage Cell Therapeutics, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5217.2M
Enterprise Value 3185.19M
Trailing P/E N/A
Forward P/E 1-8.06
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)71.64
Price/Book (mrq)1.85
Enterprise Value/Revenue 361.08
Enterprise Value/EBITDA 6-5.32

Trading Information

Stock Price History

Beta (5Y Monthly) 3.02
52-Week Change 324.17%
S&P500 52-Week Change 320.64%
52 Week High 31.7300
52 Week Low 30.5300
50-Day Moving Average 31.0850
200-Day Moving Average 30.9337

Share Statistics

Avg Vol (3 month) 31.11M
Avg Vol (10 day) 3856.53k
Shares Outstanding 5149.79M
Float 107.5M
% Held by Insiders 15.67%
% Held by Institutions 142.48%
Shares Short (Jan 30, 2020) 46.54M
Short Ratio (Jan 30, 2020) 47.07
Short % of Float (Jan 30, 2020) 46.12%
Short % of Shares Outstanding (Jan 30, 2020) 44.37%
Shares Short (prior month Dec 30, 2019) 46.17M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 23:1
Last Split Date 3Oct 30, 1997

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 30, 2018
Most Recent Quarter (mrq)Sep 29, 2019


Profit Margin 0.00%
Operating Margin (ttm)-1,247.33%

Management Effectiveness

Return on Assets (ttm)-15.30%
Return on Equity (ttm)-36.66%

Income Statement

Revenue (ttm)3.03M
Revenue Per Share (ttm)0.02
Quarterly Revenue Growth (yoy)-42.30%
Gross Profit (ttm)4.69M
EBITDA -34.81M
Net Income Avi to Common (ttm)-52.18M
Diluted EPS (ttm)-0.3730
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)35.68M
Total Cash Per Share (mrq)0.24
Total Debt (mrq)5.31M
Total Debt/Equity (mrq)4.60
Current Ratio (mrq)9.99
Book Value Per Share (mrq)0.78

Cash Flow Statement

Operating Cash Flow (ttm)-32.24M
Levered Free Cash Flow (ttm)-26.78M